Technical Chemicals and Products, Inc.
This article was originally published in The Gray Sheet
Executive Summary
Firm will relocate its Pharmetrix division and close its transdermal R&D facility in Menlo Park, California upon expiration of the lease next month as part of an ongoing program to increase operating efficiency, the company announces May 19. The move comes one week after retaining Janssen/Meyers Associates, LP for investment banking services and consulting on corporate finance and strategic transactions. TCPI will maintain associated patents and continue development of its transdermal drug delivery and skin permeation technologies at corporate headquarters in Pompano Beach, Florida. The firm says it is currently discussing development of the Pharmetrix product and patent portfolios with several pharmaceutical companies
You may also be interested in...
Cochlear’s Osia System Receives Expanded FDA Clearance For Use In Younger Children
Kids ages 5 and up now can benefit from Cochlear’s Osia implant and sound processor, indicated for hearing loss, mixed hearing loss and single-sided sensorineural deafness.
MAISI: Navigating The 'Valley Of Death' In Medtech Research Translation
Translating research from proof of concept to clinical investigations is a difficult hurdle to overcome. To succeed, researchers need to design their technology for industrial standard manufacturing early on, Anne Vanhoestenberghe, director for the Manufacture of Active Implants and Surgical Instruments (MAISI), told Medtech Insight.
Incyte Hopes To Augment Immune/Inflammation Pipeline With Escient Deal
Incyte will pay $750m to acquire privately held Escient and its first-in-class oral antagonists of Mas-related G protein-coupled receptors X2 and X4.